DK1086706T3 - Stabiliserede sammensætninger indeholdende nootropiske lægemidler - Google Patents

Stabiliserede sammensætninger indeholdende nootropiske lægemidler

Info

Publication number
DK1086706T3
DK1086706T3 DK99910793T DK99910793T DK1086706T3 DK 1086706 T3 DK1086706 T3 DK 1086706T3 DK 99910793 T DK99910793 T DK 99910793T DK 99910793 T DK99910793 T DK 99910793T DK 1086706 T3 DK1086706 T3 DK 1086706T3
Authority
DK
Denmark
Prior art keywords
acid
compositions containing
stabilized compositions
nootropic drugs
antidementia medicament
Prior art date
Application number
DK99910793T
Other languages
English (en)
Inventor
Akira Kato
Tsutomu Harada
Naokazu Murahashi
Yukiko Sugaya
Hidenobu Ando
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14235351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1086706(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DK1086706T3 publication Critical patent/DK1086706T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK99910793T 1999-03-31 1999-03-31 Stabiliserede sammensætninger indeholdende nootropiske lægemidler DK1086706T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP1999/001686 WO2000059544A1 (fr) 1999-03-31 1999-03-31 Compositions stabilisees contenant des medicaments nootropes

Publications (1)

Publication Number Publication Date
DK1086706T3 true DK1086706T3 (da) 2004-03-08

Family

ID=14235351

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910793T DK1086706T3 (da) 1999-03-31 1999-03-31 Stabiliserede sammensætninger indeholdende nootropiske lægemidler

Country Status (8)

Country Link
US (1) US6372760B1 (da)
EP (1) EP1086706B1 (da)
AT (1) ATE254928T1 (da)
DE (1) DE69913138T2 (da)
DK (1) DK1086706T3 (da)
ES (1) ES2211056T3 (da)
PT (1) PT1086706E (da)
WO (1) WO2000059544A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6193993B1 (en) * 1998-03-03 2001-02-27 Eisai Co., Ltd. Suppository containing an antidementia medicament
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
DE60124730T2 (de) 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20040258741A1 (en) * 2001-10-17 2004-12-23 Takaaki Terahara Percutaneous absorption preparations
JPWO2003066100A1 (ja) * 2002-02-07 2005-05-26 エーザイ株式会社 発毛促進剤、経皮適用製剤及び発毛促進方法
IL150509A (en) 2002-07-01 2007-07-04 Joseph Kaspi Pharmaceutical preparations containing donafazil hydrochloride
US20060014801A1 (en) * 2002-11-22 2006-01-19 The Johns Hopkins University Prevention and treatment of cognitive impairment using (R)-(-)-5-methyl-1-nicotynoyl-2-pyrazoline (MNP) and analogs
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
EP1608371A1 (en) * 2003-03-21 2005-12-28 Ranbaxy Laboratories, Ltd. Process for the preparation of donepezil and derivatives thereof
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
CA2552221A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
US20050267077A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
HUP0401850A3 (en) * 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
DE102004046497A1 (de) * 2004-09-23 2006-04-06 Helm Ag Donepezil-Salze
IL171137A (en) * 2004-09-29 2012-01-31 Chemagis Ltd Use of purified malt donfazil for the preparation of pure pharmaceutical amorphous donfazil hydrochloride
SI1811957T1 (sl) 2004-10-19 2009-04-30 Krka, Tovarna Zdravil, D.D., Novo Mesto Trden farmacevtski sestavek, ki obsega donepezil hidroklorid
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
JP5084496B2 (ja) * 2005-02-04 2012-11-28 久光製薬株式会社 経皮吸収貼付剤
WO2007010910A1 (en) * 2005-07-15 2007-01-25 Eisai R & D Management Co., Ltd. 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl]-methyl piperidine p-toluenesulfonate or crystal thereof
EA200800360A1 (ru) * 2005-07-22 2008-06-30 Мириад Дженетикс, Инк. Формуляции с высоким содержанием лекарства и дозированные формы
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB0614586D0 (en) * 2006-07-22 2006-08-30 Pliva Istrazivacki Inst D O O Pharmaceutical Formulation
EP2420235A1 (en) 2006-10-27 2012-02-22 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
KR20090086565A (ko) * 2006-12-01 2009-08-13 닛토덴코 가부시키가이샤 안정화된 도네페질 함유 접착 제제
KR101408454B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 도네페질 함유 접착 제제의 착색을 억제하는 방법 및 도네페질의 친척 물질의 생성량을 감소시키는 방법
KR101408500B1 (ko) * 2006-12-01 2014-06-17 닛토덴코 가부시키가이샤 안정화된 도네페질 함유 접착 제제
RU2435570C2 (ru) * 2006-12-01 2011-12-10 Нитто Денко Корпорейшн Композиция для чрескожного всасывания
DE102007034633A1 (de) 2007-04-05 2009-01-29 Nano-X Gmbh Beschichtungsmaterial mit einer katalytischen Aktivität und Verwendung des Beschichtungsmaterials
DE102007016946A1 (de) 2007-04-05 2008-10-09 Nano-X Gmbh Beschichtungsmaterial mit einer katalytischen Aktivität und Verwendung des Beschichtungsmaterials
WO2011100373A1 (en) * 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
DK2575769T3 (da) * 2010-02-17 2016-09-26 Veloxis Pharmaceuticals As Stabiliseret tacrolismussammensætning
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
GR1007368B (el) 2010-05-27 2011-08-02 Alapis Α.Β.Ε.Ε., Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια των συμπτωματων της ανοιας
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2012053016A1 (en) 2010-10-22 2012-04-26 Cadila Healthcare Limited Sustained release pharmaceutical compositions of donepezil
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
EP2502620A1 (en) 2011-03-24 2012-09-26 Krka Tovarna Zdravil, D.D., Novo Mesto Solid pharmaceutical composition comprising donepezil
WO2014007774A1 (en) 2012-07-02 2014-01-09 Mahmut Bilgic Water soluble formulations comprising a piperidine derivative active agent
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
KR101982018B1 (ko) 2015-12-21 2019-05-24 주식회사 에프티넷 리튬 조촉매를 첨가하여 촉매의 활성도를 증가시킨 촉매 코팅 필터
US10369187B2 (en) 2017-02-09 2019-08-06 Vanderbilt University Peptide regulators of JNK family kinases
EP3888636A4 (en) * 2018-11-26 2022-08-17 Ebabio Inc. EUTECTIC DONEPEZI MIX AND USE THEREOF
KR102115102B1 (ko) 2018-12-21 2020-05-26 동아에스티 주식회사 안정화된 도네페질 함유 경피 흡수제제

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247676A1 (de) * 1982-12-23 1984-06-28 A. Nattermann & Cie GmbH, 5000 Köln Galenische form fuer amitriptylinoxid und verfahren zur herstellung
US5428043A (en) * 1990-02-08 1995-06-27 Pfizer Inc. Tricyclic-cyclic amines as novel cholinesterase inhibitors
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
JP2770571B2 (ja) 1993-04-28 1998-07-02 吉富製薬株式会社 安定化された注射剤および注射剤の安定化法
US6323195B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
JP3136306B2 (ja) 1993-10-26 2001-02-19 丸石製薬株式会社 静脈注射用ニトロプルシドナトリウム注射剤
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
JP3797764B2 (ja) 1997-10-01 2006-07-19 エーザイ株式会社 光安定化組成物
KR100764520B1 (ko) * 1998-08-28 2007-10-09 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물

Also Published As

Publication number Publication date
EP1086706A4 (en) 2002-05-22
PT1086706E (pt) 2004-02-27
EP1086706A1 (en) 2001-03-28
US6372760B1 (en) 2002-04-16
ATE254928T1 (de) 2003-12-15
DE69913138T2 (de) 2004-08-26
DE69913138D1 (de) 2004-01-08
WO2000059544A1 (fr) 2000-10-12
EP1086706B1 (en) 2003-11-26
ES2211056T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
DK1086706T3 (da) Stabiliserede sammensætninger indeholdende nootropiske lægemidler
EE200200357A (et) Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid
EE200000759A (et) Farmatseutilised kompositsioonid kahe või enama toimeainega aerosoolidele
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
DK1123120T3 (da) Medicinsk aerosolformulering
NO20024891D0 (no) Farmasöytiske sammensetninger
NO20040564L (no) Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DK1273299T3 (da) Minoxidilinindeholdende praparater
DE69918105D1 (de) Orale zubereitung enthaltend einen biguanid und eine organische säure
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
SE0102843D0 (sv) Stabilized oral pharmaceutical composition containing lodide and lodate and method
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ATE438626T1 (de) 4,4-difluor-1,2,3,4-tetrahydro-5h-1- benzazepinderivate und deren salze
IL174336A0 (en) Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient
IL139318A0 (en) Sugar alcohol mixtures as therapeutic agents and pharmaceutical compositions containing the same
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
SE8600658D0 (sv) Novel composition of matter
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
ATE499114T1 (de) Stabilisierte wässrige erythropoietinhaltige arzneizusammensetzungen
NO20041878D0 (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
ATE241983T1 (de) Paracetamol und drotaverin enthaltende zusammensetzung
ATE526833T1 (de) Teigzusammensetzung enthaltend eingekapselte organische säure und antimikrobiellen wirkstoff
AU2002363776A1 (en) Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel